Figure 7.

LINC00941 depletion inhibits PDAC growth in vivo

(A) Subcutaneous xenografts transplanted with PANC-1 control and LINC00941 knockdown cells (n = 5). Scale bar, 1 cm. (B) Tumor growth curve of subcutaneous xenografts. (C) Tumor weight of subcutaneous xenografts. (D) Representative IHC staining results of proliferating cell nuclear antigen (PCNA), Yes1 associated transcriptional regulator (YAP1), glucose transporter type 1 (GLUT1), hexokinase 2 (HK2), and lactate dehydrogenase A (LDHA) in subcutaneous xenografts. (E) Representative bioluminescence photograph of mice orthotopically implanted with luciferase-expressing control and LINC00941 knockdown PDAC cells, treated with gemcitabine (50 mg/kg) or not. (F) Overall survival of orthotopical PDAC mice. (G) Representative IHC staining results of PCNA, YAP1, GLUT1, HK2, and LDHA in orthotopically implanted mice. (B, C, and E) Statistical significances were calculated using two-tailed Student’s t tests to compare with the NC or control group. (F) Statistical significances were calculated using log-rank Cox test. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001.